Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY2023 Earnings Presentation
25 slides from Morepen Laboratories's earnings presentation, Feb 13, 2023
Slide 1: Exchange filing cover letter for Investors Presentation
Date: 13/02/2023 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors Presentation (Q3’ FY23) February 2023 Dear Sir
Slide 2: Morepen Laboratories Q3'FY23 Earnings Presentation
MOREPEN LABORATORIES LIMITED Q3'FY23 earnings Presentation - FEB 2023
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied
Slide 4: Quarterly Highlights
QUARTERLY HIGHLIGHTS During the current Quarter Q3'FY23, the business has stabilised post Covid period fluctuations, and is on the recovery path. Q3'FY23 standalone revenues at Rs.345.81 crores are short by 7.8% against Rs. 374.90 crores in the same quarter last year. During last four years, standal
Slide 5: Consolidated Quarterly
CONSOLIDATED quarterly performance
Slide 6: Revenue Growth (Standalone)
standalone REVENUE GROWTH 35% CAGR Rs. in crores 1,500 ^30% 1460 26% CAGR 1124 400 1,000 1005 375 346 801 300 up 59% from 293 pre-covid level 500 200 218 100 0 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 7: Revenue Growth (Consolidated)
CONSOLIDATED REVENUE GROWTH 34% CAGR Rs. in crores 2,000 14% CAGR ^30% 1,500 1557 400 399 1200 350 1,000 1057 300 up 49% from 310 pre-covid level 863 200 235 500 100 0 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 8: Business Segments
CONSOLIDATED BUSINESS SEGMENTS API BUSINESS MEDICAL DEVICES FORMULATIONS OTC (SUBSIDIARY)
Slide 9: Business Wise Performance
BUSINESS WISE PERFORMANCE API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC -8% -9% ^2% -18% 250 100 50 30 200 232.95 93.66 75 85.57 40 26.80 213.60 44.27 45.23 150 20 50 30 21.99 100 20 25 10 50 10 0 0 Q3'FY22 Q3'FY23 Q3'FY22 Q3'FY23 0 0 Q3'FY22 Q3'FY23 Q3'FY22 Q3'FY23
Slide 10: Segment Wise Breakup
STANDALONE SEGMENT WISE BREAKUP Formulations 13.4% share 9M FY'22 9M'FY23 API 60.8% 4.30% Diagnostic Devices 56.5% 25.7% API 60.8% Diagnostics 25.7% 6.00% 31.7% revenue split 9M'FY'23 formulations 13.5% 1.70% 11.8%
Slide 11: API Business
API BUSINESS leadership through quality
Slide 12: API Revenue CAGR 17%
api business -Standalone API REVENUE 35% CAGR Rs. in crores 1,000 ^26% 858 CAGR 17% 750 250 683 608 232.95 500 200 213.60 474 up 62% from 150 165.03 pre-covid level 250 131.96 100 50 0 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 13: POC Medical Devices
POC MEDICAL DEVICES market leadership
Slide 14: POC Revenue CAGR 26%
POC medical devices POC REVENUE 58% CAGR Rs. in crores 500 400 ^46% CAGR 26% 419 100 93.66 300 87.58 85.57 287 75 257 200 up100% from 168 50 pre-covid level 100 42.87 25 0 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 15: Gluco Meter Revenue CAGR 32%
POC medical devices GLUCO METER REVENUE 52% CAGR Rs. in crores 300 ^55% 279 CAGR 32% 200 75 200 180 63.14 63.03 50 54.55 100 120 up 129% from pre-covid level 25 27.48 0 FY'20 FY'21 FY'22 9M'23 0 Annual performance Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Q3'FY23 performance
Slide 16: BP Monitor Revenue CAGR 38%
POC medical devices BP MONITOR REVENUE 70% CAGR Rs. in crores 100 ^33% 75 84 CAGR 38% 30 63 50 26.79 20 19.29 25 29 45 16.23 10 161% growth from pre-covid level 0 6.22 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 17: Formulations
FORMULATIONS brandeD formulations in india
Slide 18: Formulations Revenue CAGR 9%
FORMULATIONS-standalone FORMULATIONS REVENUE 11% CAGR Rs. in crores 200 ^29% 150 169 CAGR 9% 138 50 131 134 39.90 up 25% from 100 40 45.23 44.27 pre-covid level 35.52 36.69 30 50 20 10 0 FY'20 FY'21 FY'22 9M'23 0 Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Annual performance Q3'FY23 performance
Slide 19: OTC & Nutrition
Dr. Morepen® OTC & NUTRITION
Slide 20: Gross Revenue CAGR 8%
GROSS REVENUE 28% CAGR Rs. in crores 125 ^23% 100 106 CAGR 8% 86 75 30 71 65 26.80 50 up25% from 20 21.99 pre-covid level 18.35 25 17.65 10 0 FY'20 FY'21 FY'22 9M'23 0 Annual performance Q3'FY20 Q3'FY21 Q3'FY22 Q3'FY23 Q3'FY23 performance
Slide 21: Brand Portfolio CAGR 16%
BRAND PORTFOLIO an established national household brand with extensive reach and trust 36% CAGR Rs. in crores ^36% 750 685 CAGR 16% 500 504 200 504 OTC 14.2% 371 Rx 150 162.54 150.71 250 154.27 up 57% from 34.8% pre-covid level 100 96.04 0 50 FY'20 FY'21 FY'22 9M'23 Devices 51% 0 Annual performance
Slide 22: Financial Highlights
FINANCIAL highlights
Slide 23: Revenue Highlights (Q3) Standalone
standalone REVENUE HIGHLIGHTS (Q3) Rs. in crores net revenue EBIDTA PROFIT AFTER TAX 400 40 25 384.22 374.90 300 345.55 345.81 20 21.51 30 33.18 275.11 27.96 15 16.52 200 20 21.56 22.63 14.27 10 12.57 100 10 14.32 5 6.87 0 0 0 Q3'FY22 Q4'FY22 Q1'FY23 Q2'FY23 Q3'FY23 Q3'FY22 Q4'FY22 Q1'FY23 Q2'FY23 Q
Slide 24: Revenue Highlights (Q3) Consolidated
CONSOLIDATED REVENUE HIGHLIGHTS (Q3) Rs. in crores net revenue EBIDTA PROFIT AFTER TAX 500 40 25 400 34.81 20 399.19 403.85 30 21.52 371.46 349.69 29.78 300 15 303.31 15.81 20 21.85 21.74 200 10 12.32 15.46 9.00 10 100 5 5.63 0 0 0 Q3'FY22 Q4'FY22 Q1'FY23 Q2'FY23 Q3'FY23 Q3'FY22 Q4'FY22 Q1'FY23 Q2'F
Slide 25: Thank you
Thank you a glimpese of Corporate office in delhi ncr
Morepen Laboratories — Q3 FY2023 Earnings Presentation on 6ix